263 related articles for article (PubMed ID: 16946299)
1. CD200 is a new prognostic factor in multiple myeloma.
Moreaux J; Hose D; Reme T; Jourdan E; Hundemer M; Legouffe E; Moine P; Bourin P; Moos M; Corre J; Möhler T; De Vos J; Rossi JF; Goldschmidt H; Klein B
Blood; 2006 Dec; 108(13):4194-7. PubMed ID: 16946299
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma.
Aref S; Azmy E; El-Gilany AH
Hematol Oncol; 2017 Mar; 35(1):51-57. PubMed ID: 26033514
[TBL] [Abstract][Full Text] [Related]
3. [CD200 protein, bad prognostic in patients with multiple myeloma].
Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Pérez-Retiguin F; Reyes-Maldonado E; Maillet D; Montiel-Cervantes LA
Rev Med Inst Mex Seguro Soc; 2015; 53(4):438-43. PubMed ID: 26177431
[TBL] [Abstract][Full Text] [Related]
4. CD200: a putative therapeutic target in cancer.
Moreaux J; Veyrune JL; Reme T; De Vos J; Klein B
Biochem Biophys Res Commun; 2008 Feb; 366(1):117-22. PubMed ID: 18060862
[TBL] [Abstract][Full Text] [Related]
5. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
[TBL] [Abstract][Full Text] [Related]
6. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma.
Douds JJ; Long DJ; Kim AS; Li S
J Clin Pathol; 2014 Sep; 67(9):792-6. PubMed ID: 24958785
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.
Alapat D; Coviello-Malle J; Owens R; Qu P; Barlogie B; Shaughnessy JD; Lorsbach RB
Am J Clin Pathol; 2012 Jan; 137(1):93-100. PubMed ID: 22180482
[TBL] [Abstract][Full Text] [Related]
9. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler GM; Benner A; Hundemer M; Rème T; Shaughnessy JD; Barlogie B; Bertsch U; Hillengass J; Ho AD; Pantesco V; Jauch A; De Vos J; Rossi JF; Möhler T; Klein B; Hose D
Oncogene; 2009 Nov; 28(44):3866-79. PubMed ID: 19718049
[TBL] [Abstract][Full Text] [Related]
10. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
Mahtouk K; Hose D; Raynaud P; Hundemer M; Jourdan M; Jourdan E; Pantesco V; Baudard M; De Vos J; Larroque M; Moehler T; Rossi JF; Rème T; Goldschmidt H; Klein B
Blood; 2007 Jun; 109(11):4914-23. PubMed ID: 17339423
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
12. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
Conticello C; Giuffrida R; Parrinello N; Buccheri S; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F
Leuk Res; 2013 Dec; 37(12):1616-21. PubMed ID: 24183830
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between Expression of CD200 and Regulatory T Cells in Multiple Myeloma and Its Significance in Prognostic Stratification].
Zhu MX; Wan WL; Li HS; Wang YF; Wang J; Ling HS; Yan XX; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1427-1432. PubMed ID: 27784369
[TBL] [Abstract][Full Text] [Related]
14. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
Moreaux J; Cremer FW; Reme T; Raab M; Mahtouk K; Kaukel P; Pantesco V; De Vos J; Jourdan E; Jauch A; Legouffe E; Moos M; Fiol G; Goldschmidt H; Rossi JF; Hose D; Klein B
Blood; 2005 Aug; 106(3):1021-30. PubMed ID: 15827134
[TBL] [Abstract][Full Text] [Related]
15. Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.
Mahtouk K; Hose D; De Vos J; Moreaux J; Jourdan M; Rossi JF; Rème T; Goldschmidt H; Klein B
Clin Cancer Res; 2007 Dec; 13(24):7289-95. PubMed ID: 18094409
[TBL] [Abstract][Full Text] [Related]
16. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.
Mahtouk K; Moreaux J; Hose D; Rème T; Meissner T; Jourdan M; Rossi JF; Pals ST; Goldschmidt H; Klein B
BMC Cancer; 2010 May; 10():198. PubMed ID: 20465808
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
18. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor.
Rygiel TP; Karnam G; Goverse G; van der Marel AP; Greuter MJ; van Schaarenburg RA; Visser WF; Brenkman AB; Molenaar R; Hoek RM; Mebius RE; Meyaard L
Oncogene; 2012 Jun; 31(24):2979-88. PubMed ID: 22020332
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
